A French venture capital firm historically focused on deep-tech and hardware but is now broadening their scope to sectors such as the intersection between deep-tech and life sciences. Currently investing from their second fund of USD $75M, the firm participates in Pre-Seed and Seed rounds, typically allocating between USD $500K – $2.5M. The firm prefers to lead or co-lead and looks at companies in Europe and the U.S. 

In terms of life sciences, the firm is open to digital health deep-tech companies but are not interested in apps. The firm does not look at traditional therapeutics but will look at therapeutics with a data component or multi-asset and platform technologies. The firm is also open to diagnostics, non-invasive medical devices, surgical tools, and biomanufacturing. The firm looks at companies that are in their pre-clinical and development stages. The firm is disease-agnostic. 

The firm may take a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm founded in 2024 and has USD $40M under management seeks to invest in Pre-Seed and Seed stage longevity biotech companies developing technologies that can significantly extend healthy human lifespan and are scalable for everyone. Initial check size ranges between USD $250K – $1.5M with the ability to lead or co-lead. The firm is open to global companies but prefers the US, UK, and EU. 

The firm is open to all technologies, except single assets, that address longevity. Areas of interest include breakthroughs in multiple areas including AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, tissue engineering, and more. Every company they invest in must have the potential to extend healthy human lifespan by at least 10+ years. Companies of interest are typically still in pre-clinical stages. The firm seeks out companies with a strong ethical foundation and robust scientific backing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture studio and accelerator that was created as a joint venture between a traditional VC firm and CRO identifies promising early-stage technologies with academic institutional foundations that are not yet ready for institutional investment. The group provides hands-on operational expertise and up to $5M of funding per company to help translate these innovations into viable startups. 
 
In their model, the institutional principal investigators are positioned as company founders, while the group’s CEO and CSO serve as interim executives to help guide early development in conjunction with the broader team. Once the company demonstrates sufficient progress, the VC firm that backs the group would plan to lead a Series A financing. 
 
The group is evolving its traditional venture studio approach to work with early-stage companies that have already been incorporated, and which would benefit from the same operational and strategic support and funding to accelerate achievement of proof of concept and enable access to VC funding or pharma partnerships. The group is currently focused on technologies and companies that are based in the U.S. 

The group focuses exclusively on traditional therapeutics. Although modality-agnostic, the group prefers traditional modalities such as small molecules and biologics. In terms of indication areas, there is particular interest in oncology, kidney disease, fibrosis, immunology and inflammation, and cardiovascular disease. However, the group remains open to other opportunities that address compelling unmet needs and present a sizeable market opportunity. The group targets early programs and considers in-clinic assets to be too late-stage for its investment model. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital and private equity firm focuses on investments in the life sciences sector, with a primary emphasis on pharmaceuticals and therapeutics, and a secondary interest in medical devices. The firm invests from Series A through growth-stage transactions and is currently deploying capital from its third fund. Typical investment sizes range from $10 million to $40 million. 

The firm prioritizes opportunities with a de-risked clinical development pathway, such as those involving repurposed or reformulated drugs, established mechanisms of action, 505(b)(2) regulatory strategies, or programs with proof-of-concept clinical data. For therapeutic assets, the firm primarily targets clinical-stage companies, ideally with completed Phase I trials. For medical devices, the firm considers clinical-stage opportunities with a clear regulatory and commercialization path. The firm is indication-agnostic but maintains a strong interest in 505(b)(2) products.  
 
The firm seeks companies with a clearly defined path to regulatory approval, supported by robust intellectual property and market exclusivity. It plays an active role in its portfolio companies and takes a board seat in every investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

This early-stage venture fund, with offices in Western Europe, is led by a team with deep expertise across venture funding, company building, and therapeutic development. The firm is currently focused on cell and gene therapy, with particular interest in the manufacturing technologies that support these modalities. 

The firm is especially interested in therapeutic platforms at the pre-clinical stage, including cutting-edge cell therapies for regenerative medicine and autoimmune conditions that require localized manufacturing capabilities. It seeks to support breakthrough technologies at the seed stage. 

The firm typically takes an active role in its portfolio companies, frequently leading rounds, providing strategic guidance, and ensuring board-level engagement, either by taking a board seat directly or placing a qualified expert. In addition to company creation, the firm also invests in existing ventures, often syndicating with other institutional investors to support early-stage growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.